FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207029238> ?p ?o ?g. }

• W4207029238 endingPage "185.e7" @default.
• W4207029238 startingPage "185.e1" @default.
• W4207029238 abstract "Although tacrolimus and sirolimus (TAC/SIR) is an accepted graft-versus-host disease (GVHD) prophylaxis regimen following allogeneic hematopoietic cell transplantation (HCT), toxicity from this regimen can lead to premature discontinuation of immunosuppression. There are limited studies reporting outcomes and subsequent treatment of patients with TAC/SIR intolerance. This study was conducted to assess the outcomes of patients with TAC/SIR intolerance and guide their subsequent management. We retrospectively analyzed transplantation outcomes of consecutive adult patients at Moffitt Cancer Center who underwent allogeneic HCT with TAC/SIR as GVHD prophylaxis between 2009 and 2018. TAC/SIR intolerance was defined as discontinuation of either TAC or SIR due to toxicity before post-transplantation day +100. A total of 777 patients met the inclusion criteria. The median duration of follow-up was 22 months (range, 0.2 to 125 months). Intolerance occurred in 13% (n = 104) of the patients at a median of 30 days (range, 5 to 90 days). The most common causes of intolerance were acute kidney injury (n = 53; 51%), thrombotic microangiopathy (n = 31; 28%), and veno-occlusive disease (n = 23; 22%). The cumulative incidence of grade II-IV acute GVHD at 100 days was 50% (95% CI, 39% to 64%) in the TAC/SIR-intolerant patients and 25% (95% CI, 22% to 29%) in patients tolerant to this regimen (P < .0001). In multivariate analyses, the incidence of grade II-IV 4 acute GVHD was significantly higher in the TAC/SIR-intolerant patients (hazard ratio [HR], 2.40; 95% CI, 1.59 to 3.61; P < .0001). Similarly, in multivariate analyses, the TAC/SIR-intolerant patients had a higher incidence of chronic GVHD (HR, 1.48; 95% CI, 1.03 to 2.12; P = .03). The nonrelapse mortality (NRM) at 1 year was 47% (95% CI, 38% to 59%) in the TAC/SIR-intolerant patients and 12% (95% CI, 10% to 15%) in those tolerant to the regimen (P < .0001). The 2-year relapse-free survival was 35% (95% CI, 25% to 44%) in the TAC/SIR-intolerant patients and 60% (95% CI, 57% to 65%) in the TAC/SIR-tolerant patients (HR, 2.30; 95% CI, 1.61 to 3.28; P < .0001). Intolerance stratified by early (≤30 days) versus late (31 to 100 days) significantly affected the cumulative incidence of acute GVHD at 75% (early; 95% CI, 59% to 94%) versus 33% (late; 95% CI, 21% to 50%) (P = .001), as well as the cumulative incidence of NRM at 61% (early; 95% CI, 48% to 77%) versus 35% (late; 95% CI, 24% to 51%) (P = .006). Most patients who developed TAC/SIR intolerance were switched to an alternative 2-drug regimen (71 of 104; 68%), most commonly mycophenolate mofetil in addition to continuing TAC or SIR (68 of 71; 96%). Overall, TAC/SIR intolerance was associated with poorer outcomes. Early intolerance contributed to a higher risk of acute GVHD, increased NRM, and inferior survival. Patients with early intolerance were often switched to an alternative agent, and patients with late intolerance tended to be continued on single-drug therapy without substitution. The use of single-drug versus 2-drug regimens after intolerance did not appear to affect outcomes. Management strategies to mitigate the risks of intolerance are warranted." @default.
• W4207029238 created "2022-01-26" @default.
• W4207029238 creator A5004190194 @default.
• W4207029238 creator A5009719497 @default.
• W4207029238 creator A5009934497 @default.
• W4207029238 creator A5015707456 @default.
• W4207029238 creator A5017228255 @default.
• W4207029238 creator A5017961539 @default.
• W4207029238 creator A5033799974 @default.
• W4207029238 creator A5035905546 @default.
• W4207029238 creator A5041095483 @default.
• W4207029238 creator A5054866014 @default.
• W4207029238 creator A5055261814 @default.
• W4207029238 creator A5062691289 @default.
• W4207029238 creator A5065360941 @default.
• W4207029238 creator A5068862906 @default.
• W4207029238 creator A5069717476 @default.
• W4207029238 creator A5076100445 @default.
• W4207029238 creator A5079098249 @default.
• W4207029238 creator A5083687455 @default.
• W4207029238 date "2022-04-01" @default.
• W4207029238 modified "2023-10-16" @default.
• W4207029238 title "Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation" @default.
• W4207029238 cites W1972184826 @default.
• W4207029238 cites W1975946124 @default.
• W4207029238 cites W1993486845 @default.
• W4207029238 cites W2003500862 @default.
• W4207029238 cites W2008349138 @default.
• W4207029238 cites W2017821630 @default.
• W4207029238 cites W2027086946 @default.
• W4207029238 cites W2028489100 @default.
• W4207029238 cites W2048313228 @default.
• W4207029238 cites W2051785605 @default.
• W4207029238 cites W2054355000 @default.
• W4207029238 cites W2055981604 @default.
• W4207029238 cites W2073140442 @default.
• W4207029238 cites W2078042245 @default.
• W4207029238 cites W2082814420 @default.
• W4207029238 cites W2085290177 @default.
• W4207029238 cites W2123069998 @default.
• W4207029238 cites W2139071236 @default.
• W4207029238 cites W2141010787 @default.
• W4207029238 cites W2151348405 @default.
• W4207029238 cites W2379365975 @default.
• W4207029238 cites W2396687607 @default.
• W4207029238 cites W2586193330 @default.
• W4207029238 cites W2604816573 @default.
• W4207029238 cites W2804399078 @default.
• W4207029238 cites W2808074980 @default.
• W4207029238 cites W2898432878 @default.
• W4207029238 cites W3001276384 @default.
• W4207029238 cites W3009429865 @default.
• W4207029238 cites W3127311881 @default.
• W4207029238 doi "https://doi.org/10.1016/j.jtct.2022.01.003" @default.
• W4207029238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35017119" @default.
• W4207029238 hasPublicationYear "2022" @default.
• W4207029238 type Work @default.
• W4207029238 citedByCount "2" @default.
• W4207029238 countsByYear W42070292382023 @default.
• W4207029238 crossrefType "journal-article" @default.
• W4207029238 hasAuthorship W4207029238A5004190194 @default.
• W4207029238 hasAuthorship W4207029238A5009719497 @default.
• W4207029238 hasAuthorship W4207029238A5009934497 @default.
• W4207029238 hasAuthorship W4207029238A5015707456 @default.
• W4207029238 hasAuthorship W4207029238A5017228255 @default.
• W4207029238 hasAuthorship W4207029238A5017961539 @default.
• W4207029238 hasAuthorship W4207029238A5033799974 @default.
• W4207029238 hasAuthorship W4207029238A5035905546 @default.
• W4207029238 hasAuthorship W4207029238A5041095483 @default.
• W4207029238 hasAuthorship W4207029238A5054866014 @default.
• W4207029238 hasAuthorship W4207029238A5055261814 @default.
• W4207029238 hasAuthorship W4207029238A5062691289 @default.
• W4207029238 hasAuthorship W4207029238A5065360941 @default.
• W4207029238 hasAuthorship W4207029238A5068862906 @default.
• W4207029238 hasAuthorship W4207029238A5069717476 @default.
• W4207029238 hasAuthorship W4207029238A5076100445 @default.
• W4207029238 hasAuthorship W4207029238A5079098249 @default.
• W4207029238 hasAuthorship W4207029238A5083687455 @default.
• W4207029238 hasBestOaLocation W42070292381 @default.
• W4207029238 hasConcept C126322002 @default.
• W4207029238 hasConcept C141071460 @default.
• W4207029238 hasConcept C207103383 @default.
• W4207029238 hasConcept C2777408962 @default.
• W4207029238 hasConcept C2777878052 @default.
• W4207029238 hasConcept C2778715236 @default.
• W4207029238 hasConcept C2779134260 @default.
• W4207029238 hasConcept C2779972918 @default.
• W4207029238 hasConcept C2780252810 @default.
• W4207029238 hasConcept C2781413609 @default.
• W4207029238 hasConcept C2909675724 @default.
• W4207029238 hasConcept C2911091166 @default.
• W4207029238 hasConcept C44249647 @default.
• W4207029238 hasConcept C71924100 @default.
• W4207029238 hasConcept C88879693 @default.
• W4207029238 hasConcept C90924648 @default.
• W4207029238 hasConceptScore W4207029238C126322002 @default.
• W4207029238 hasConceptScore W4207029238C141071460 @default.
• W4207029238 hasConceptScore W4207029238C207103383 @default.

• next